Import duty boosts equipment costs in India
This article was originally published in Clinica
A leading Indian cardiologist has criticised successive governments for failing to reduce import duty on high-tech medical equipment to an acceptable level. Despite progressive cuts in tariffs from 300% to the current 47%, Dr S Ramesh, director of cardiovascular science at Bangalore's Mallya Hospital, believes duty is still too high.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.